- Follow Us
Microarray-powered
Custom Monoclonal Antibody Development and Validation
Our unique platform addresses the need for monoclonal antibodies with unprecedented specificity to native or denatured proteins.
REQUEST INFOMore Than 20,000+ Antigens Available
Using HuProt™ Human Proteome Microarray to validate the final product, your antibody is screened for cross-reactivity against the largest collection of human proteins on a single slide – representing approximately 75% of the human proteome.
CDI Labs offers a streamlined monoclonal antibody development, production, and purification process, complemented by HuProt™ microarray specificity validation, typically completed in about 8 weeks. This milestone-driven, four-phase process includes client reporting and assessments at each step, with invoicing initiated at Phase 1 and at the completion of each phase thereafter. Milestones provide potential endpoints, guided by project requirements or adjustments if results deviate from expectations. Our antibody development pipeline handles up to 25 antigens per month but is scalable to accommodate your needs. Our mission is to establish an efficient, standardized pipeline to deliver highly specific monoclonal antibodies tailored to your projects.
Monospecificity in 8 Weeks
Our antibody development platform addresses the urgent need for monoclonal antibodies with unprecedented specificity to native or denatured proteins.
Quote
Project Specification
Antigen design, immunization strategy and screening methodology are critical to achieving high-value results. CDI Labs offers a fully-customized development process to meet the requirements and provide a quote based on deliverables.
Day 1
Phase 1
Antigen and Immunization
5-mouse immunization regimen using as little as 200 μg client-supplied protein of >80% purity or carrier-conjugated peptide. We also offer assistance in antigen design and synthesis.
Day 14
Phase 2
Fusion and Screening
2 top-responding animals are chosen, and immune cells are harvested for fusion with myeloma cells yielding multiple hybridomas. Supernatants from IgG-secreting clones are screened by ELISA.
Day 38
Phase 3
Sub-cloning, Expansion and Specificity Testing
A minimum of 5 to a maximum of 30 high-quality clones are chosen and sub-cloned. Each is expanded into 24-well plates and subsequently into T-25 flasks. Supernatants are shipped for further client evaluation.
Day 52
Phase 4
Production and Purification
Each clone is vialed, labeled and frozen. Samples of each are reserved for mycoplasma testing. Per client instructions, 3 select clones are placed into antibody production. The resulting antibodies are purified and evaluated with HuProt Human Proteome Microarray.
Day 56
Deliverables
Detailed specificity data and additional QA documentation are prepared and shipped along with the purified antibodies and all frozen clones.
Antibodies Come in a Variety of Forms Called Isotypes
Depending on the isotype, antibodies can promote cell killing, protective immune tolerance, or help educate T cells, and we can help you measure them
We believe there are undiscovered antigen-specific and isotype-restricted antibody responses involved in these conditions, and that once known, those targets can be used as biomarkers to both diagnose disease and predict treatment outcomes. Some of these discoveries may lead to new drugs and vaccines that can treat or even prevent cancer, dementia, aging, and more.
